Publications

(Displaying in Reverse Chronological Order)

  1. अनुसंधान
  2. Publications
  3. Publications
811
Ahuja BK, Jena SK, Paidi SK, Bagri S, Suresh S. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension International Journal of Pharmaceutics 2015, 478, 540-552.
812
Ajay D, Gangwal RP, Sangamwar AT. IPAT: a freely accessible software tool for analyzing multiple patent documents with inbuilt landscape visualizer Pharmaceutical Patent Analyst 2015, 4, 377-386.
813
Arfeen M, Patel R, Khan T, Bharatam PV. Molecular dynamics simulation studies of GSK-3? ATP competitive inhibitors: Understanding the factors contributing to selectivity Journal of Biomolecular Structure and Dynamics 2015, 33, 2578-2593.
814
Arora S, Haghi M, Loo CY, Traini D, Young PM, Jain S. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection Molecular Pharmaceutics 2015, 12, 2001-2009.
815
Arora S, Mahajan RR, Kushwah V, Baradia D, Misra A, Jain S. Development of voriconazole loaded large porous particles for inhalation delivery: Effect of surface forces on aerosolisation performance, assessment of in vitro safety potential and uptake by macrophages RSC Advances 2015, 5, 38030-38043.
816
Bairwa K, Jachak SM. Anti-inflammatory potential of a lipid-based formulation of a rotenoid-rich fraction prepared from Boerhavia diffusa Pharmaceutical Biology 2015, 53, 1231-1238.
817
Bairwa K, Jachak SM. Development and optimisation of 3-Acetyl-11-keto-?-boswellic acid loaded poly-lactic-co-glycolic acid-nanoparticles with enhanced oral bioavailability and in-vivo anti-inflammatory activity in rats Journal of Pharmacy and Pharmacology 2015, 67, 1188-1197.
818
Bajaj P, Tripathy RK, Aggarwal G, Pande AH. Expression and purification of biologically active recombinant human paraoxonase 1 from inclusion bodies of Escherichia coli Protein Expression and Purification 2015, 115, 95-101.
819
Banoth L, Thakur NS, Bhaumik J, Banerjee UC. Biocatalytic Approach for the Synthesis of Enantiopure Acebutolol as a ?1-Selective Blocker Chirality 2015, 27, 382-391.
820
Bansal D, Bhagat A, Schifano F, Gudala K. Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008-2012) Journal of Epidemiology and Global Health 2015, 5, 385-395.
821
Bansal D, Nayakallu RSR, Gudala K, Vyamasuni R, Bhansali A. Agreement between framingham risk score and united kingdom prospective diabetes study risk engine in identifying high coronary heart disease risk in North Indian population Diabetes & Metabolism Journal 2015, 39, 321-327.
822
Baviskar AT, Amrutkar SM, Trivedi N, Chaudhary V, Nayak A, Guchhait SK, Banerjee UC, Bharatam PV, Kundu CN. Switch in Site of Inhibition: A Strategy for Structure-Based Discovery of Human Topoisomerase IIa Catalytic Inhibitors ACS Medicinal Chemistry Letters 2015, 6, 481-485.
823
Beg S, Sharma G, Thanki K, Jain S, Katare OP, Singh B. Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: Systematic development, in vitro, ex vivo and in vivo evaluation International Journal of Pharmaceutics 2015, 493, 466-482.
824
Beladiya C, Tripathy RK, Bajaj P, Aggarwal G, Pande AH. Expression, purification and immobilization of recombinant AiiA enzyme onto magnetic nanoparticles Protein Expression and Purification 2015, 113, 56-62.
825
Belekar V, Lingineni K and Garg P. Classification of Breast Cancer Resistant Protein (BCRP) Inhibitors and Non-inhibitors using Machine Learning Approaches Combinatorial Chemistry & High Throughput Screening 2015, 18, 476-485.
Information: Duration to be uploaded/incorporated on archival site after the completion of process is 12 months.

2627|55|15